Freeze and drug combo takes aim at early lung cancer
NCT ID NCT07064876
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests a new combination treatment for people with early-stage non-small cell lung cancer who cannot or choose not to have surgery or radiation. The treatment uses a drug called serplulimab (given through a vein every 3 weeks for up to 6 cycles) along with cryoablation, a procedure that freezes and destroys the tumor. The goal is to see how well this combination shrinks or controls the cancer. About 25 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University, No. 180 Fenglin Road, Xuhui District,
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.